B01AC07 - Dipyridamole |
Not porphyrinogenic |
NP |
Rationale
No CYP-interactions.
Chemical description
Platelet inhibitor administered as tablets in a dose of 200 mg, Maximal plasma level is 2.6 µg/mL. Mainly excreted unmetabolized in faeces. Metabolism takes place by conjugation with glucuronic acid.
Personal communication
Andersson C, patient report: tolerated (n=1).
IPNet drug reports
Uneventful use reported in 1 patients with acute porphyria.
Similar drugs
References
| # | Citation details | PubMed ID |
|---|---|---|
| Porphyria Drug Lists | ||
| 1. | Michael Moore's List
No longer maintained
|
|
| 2. | French List
Centre Français des Porphyries
|
|
| 3. | South African List
Porphyria South Africa No longer maintained
|
|
Tradenames
Dipyridamol · Persantin 
Persantin 
Corosan · Persantin 
Attia · Dipyridamole · Ofcram PR · Persantin · Persantin Retard · Pyridantin · Trolactin 
Dipyridamol · Persantin · Pyranistole 
Attia · Dipyridamol · Dipyridamole · Persantin 
Aponova · Dipyridamol · Persantin 
Dipiridamol · Persantin 
Dipyridamole · Persantin · Pytazen · Tensadin 
Perazodin · Persantin 
Dipyridamole · Persantine 
Persantin 
Persantin 
Persantin 
Dipiridamol · Persantin 
Attia · Cerebrovase · Dipyridamole · Dipyridamole component of aggrenox · Iv persantine · Modaplate · Ofcram · Persantin · Persantine · Pyridantin · Vasyrol 
Dipiridamol 
Dipyridamole